Senior Scientist​/Principal Scientist​/Associate Director, Biotransformation

Description

* Note:

exact level depending on experience*

Vividion is a next generation biotechnology company based in San Diego that is leveraging its proprietary chemical proteomics platform to conduct proteome-wide foot printing of drug-protein interactions with unprecedented breadth and precision. Our technology allows us to screen, identify and optimize novel drugs that selectively bind virtually any protein, including proteins previously considered “undruggable”. Our pipeline and emerging programs reflect a matured and productive platform capable of delivering first in class drugs utilizing novel mechanisms of action (allosteric inhibitors, protein-protein interaction inhibitors, functional activators, degraders etc.)

against undruggable targets in the oncology and immunology space.

We prize scientific excellence, creativity, team players and we are committed to continued innovation. We have worked hard to create a collaborative and dynamic work culture where your ideas and discoveries are valued and will have an impact. We are growing and there are opportunities for mentorship and career progression.

Vividion has been recognized as a Top Workplace by The San Diego Union-Tribune from 2022 to 2025.

We are seeking a very highly motivated, collaborative biotransformation expert who is passionate and dedicated to using DMPK expertise to drive drug discovery and development programs  Biotransformation position will be responsible for all aspects of metabolite profiling, identification and associated enzymology of select projects. This position will be part of the Biotransformation group and will provide the opportunity to take on additional Biotransformation responsibilities for the broader Vividion portfolio.

This position has both technical and broader scientific advisory aspects including providing scientific and strategic input, guiding medicinal chemists in chemical series optimization, problem-solving and cross-functional collaboration, and innovation in a team environment. The successful candidate will design, execute, and manage in vitro soft-spot and tox species selection MetID studies, and definitive in vivo MetID studies. This role involves both experimental laboratory-based work and management of biotransformation studies conducted at CRO’s.

The successful candidate is expected to be well-versed in the interpretation of mass spectra, and proficient in the preparation of data summaries, presentation of results to project teams and management, authoring regulatory reports, and contributing to regulatory documents to support clinical development.

• Design and conduct non-labeled and radio labeled in vitro and in vivo biotransformation studies supporting drug discovery and development
• Execute in vitro soft-spot and tox species selection MetID studies and conduct in vivo MetID studies
• Manage and provide oversight for biotransformation studies conducted at CRO’s
• Interact with multidisciplinary project teams
• Lead DMPK studies supporting preclinical and clinical development
• Work collaboratively across functions to optimize drug candidates and understand species differences across metabolite profiles in support of toxicology studies
• Author reports, prepare data summaries and communicate results to project teams and management
• Author regulatory submission documentation including IND summaries and Investigator Brochure
• Mentor and motivate the in-house DMPK team

• PhD in Organic Chemistry, Drug Metabolism, Pharmacokinetics, Pharmaceutical Sciences, or related discipline with 7+ years of industry experience; MS/BS with 12+ years’ experience will also be considered
• Expertise in drug metabolism, in vitro enzyme kinetics, ADME assays and LC/MS bioanalytical methodology
• Experience in working with radioactivity (3H and 14C) will be a bonus
• Experience in designing, executing and reviewing biotransformation studies
• Understanding of regulatory guidance as it pertains to biotransformation including MIST
• Experience in biotransformation document preparation for regulatory submissions is a plus

• Exc…